Drug Trial Radar · NCT02786511
Longterm Follow-up of Subjects Treated With bb2121
Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 28, 2016
Primary completion
Oct 11, 2019
Study completion Oct 11, 2019
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 1, 2016
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study, that evaluated the safety and efficacy of bb2121 in subjects with relapsed or refractory B cell maturation antigen (BCMA)-expressing multiple myeloma. bb2121 is defined as autologous T lymphocytes (T cells) transduced ex vivo with anti-BCMA02 CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA suspended in cryopreservative solution. bb2121 is administered in subjects 1 time (or retreated if retreatment criteria are met) in parent clinical study. No investigational treatment will be administered in this study. After completing the parent study, eligible subjects will be followed for up to 15 years after their last bb2121 infusion in the parent study.
Conditions
- Multiple Myeloma
Interventions
Safety and efficacy assessmentsDrug
Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 15 years post-drug product infusion
- Monitoring for all Adverse Events, including Serious Adverse Events, related to the drug productTime frame: 15 years post-drug product infusion
- Monitoring for all Serious Adverse Events including any new malignancy or new diagnosis of a neurologic, rheumatologic, or hematologic disorder that is clinically significantTime frame: 5 years post-drug product infusion
- Monitoring for Multiple Myeloma-specific response according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple MyelomaTime frame: 5-15 years post-drug product infusion
- Progression Free SurvivalTime frame: 5-15 years post-drug product infusion
- Monitoring for Vector Copy Number (VCN)Time frame: 5-15 years post-drug product infusion
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Stanford Cancer Center
Palo Alto, California
National Cancer Institute
Bethesda, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Mayo Clinic Cancer Center
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai Medical Center
New York, New York
Sarah Cannon Research Institute
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.